Wedbush Expects Weaker Earnings for Bicara Therapeutics

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for Bicara Therapeutics in a research note issued to investors on Tuesday, August 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.41). Wedbush currently has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics’ Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($2.25) EPS and FY2028 earnings at ($2.16) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target for the company in a research note on Friday, May 23rd. Wall Street Zen downgraded shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Finally, HC Wainwright decreased their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating for the company in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $31.86.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $11.64 on Friday. The company has a 50 day moving average price of $10.43 and a 200-day moving average price of $11.95. Bicara Therapeutics has a fifty-two week low of $7.80 and a fifty-two week high of $28.09. The company has a market capitalization of $635.08 million and a PE ratio of -3.67.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. Vanguard Group Inc. raised its stake in Bicara Therapeutics by 1,457.9% in the fourth quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company’s stock worth $18,997,000 after buying an additional 1,020,528 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Bicara Therapeutics by 8,768.5% in the fourth quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company’s stock worth $1,128,000 after buying an additional 64,010 shares in the last quarter. Geode Capital Management LLC raised its stake in Bicara Therapeutics by 859.4% in the fourth quarter. Geode Capital Management LLC now owns 466,642 shares of the company’s stock worth $8,131,000 after buying an additional 418,003 shares in the last quarter. Wells Fargo & Company MN bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $175,000. Finally, Invesco Ltd. bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $267,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.